HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Fraud In US: Online Pharmacies Promote HIV Drug, Ammo Dealer Pitches Vitamin C

Executive Summary

Latest letters from website reviews push to 62 the number of warnings the FDA, either jointly with the FTC or on its own, has made stating that no drug has yet been approved by the agency for use in the prevention, diagnosis, treatment, mitigation or cure of COVID-19.

You may also be interested in...



FTC Targets EM Radiation ‘Blocking Patch’ Seller In Latest COVID-19 Warning Letter Salvo

The Commission serves up 35 more warning letters to companies making false and unsubstantiated COVID-19 claims, including Julie E Health, which marketed a prevention and treatment kit comprised of dietary supplements and purported EMF “remediation” products, capitalizing on conspiracy theory anxieties.

USPTO Allows Accelerated Path For COVID-19 Products Across Medical, Health Care Sectors

USPTO pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months. Prioritized examination is available solely for small entities and would save them $2,000.

Twin Websites Selling Steroids OTC Also Offered HIV, Influenza Drugs As COVID-19 Treatments

Two e-commerce sites offering steroids OTC also were offering HIV and influenza drugs as treatments for COVID-19, according to FDA warnings. The listings have been removed but the operators were asked to provide plans to remedy violations within 48 hours.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel